Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cyclosporine A 0.05% Clear all
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Novel Use of Restasis and PROSE Devices

NCT04735510
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
cyclosporine ophthalmic emulsion 0.05%
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

NCT01817582
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Lotemax, Restasis, Soothe® Lubricant Eye Drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 1, 2026, 9:52 AM EDT
Terminated Phase 4 Interventional Results available

A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity

NCT00983645
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Neoral
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Restasis for Treatment of Brittle Nails

NCT00986427
View directory record Official record
Conditions
Brittle Nails
Interventions
Restasis (cyclosporine ophthalmic emulsion) 0.05%, Refresh® Dry Eye therapy
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

NCT05322148
View directory record Official record
Conditions
Dry Eye
Interventions
Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Hemet, California • Laguna Hills, California • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT04734197
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

NCT00739349
View directory record Official record
Conditions
Dry Eye
Interventions
NOVA22007 ''Cyclosporine'', vehicle/placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lewiston, Maine
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Not applicable Interventional Results available

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

NCT00987467
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
Cyclosporin 0.05% ophthalmic
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Topical Cyclosporin for Ocular Rosacea

NCT00348335
View directory record Official record
Conditions
Rosacea
Interventions
Cyclosporine 0.05%, Ocular lubricant
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 1, 2026, 9:52 AM EDT
Completed No phase listed Observational Results available

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

NCT00717418
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine ophthalmic emulsion 0.05%, artificial tears
Drug
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Wilson, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Results available

Effect of Cequa™ in Subjects With Dry Eye Disease

NCT04357795
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solution
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Fort Myers, Florida • Jacksonville, Florida • Panama City, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

NCT00611403
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®), Artificial Tears REFRESH ENDURA®
Drug
Lead sponsor
Allergan
Industry
Eligibility
21 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

NCT00157014
View directory record Official record
Conditions
Heart Diseases, Heart Transplantation
Interventions
Tacrolimus, Cyclosporine, Mycophenolate mofetil, Methylprednisolone, Prednisone
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

NCT01319773
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine ophthalmic emulsion Formulation A, cyclosporine ophthalmic emulsion Formulation B, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®

NCT02554981
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine 0.05% Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

NCT01109056
View directory record Official record
Conditions
Pterygium
Interventions
cyclosporine ophthalmic emulsion 0.05%, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Sep 1, 2026, 9:52 AM EDT
Completed No phase listed Observational Results available

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

NCT00827255
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cyclosporine Ophthalmic Emulsion 0.05%
Drug
Lead sponsor
Allergan
Industry
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 1, 2026, 9:52 AM EDT
Terminated Phase 4 Interventional Results available

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

NCT00553735
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine A 0.05%, Arificial Tear
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

NCT00928018
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Sirolimus, Methotrexate, Tacrolimus, Cyclosporine, MMF
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 72 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 1, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

NCT03597139
View directory record Official record
Conditions
Dry Eye
Interventions
Voclosporin Ophthalmic Solution, Restasis®
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Garden Grove, California • Mission Hills, California • Rancho Cordova, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 1, 2026, 9:52 AM EDT